What patent dispute involving Roche and Perjeta is mentioned for Australia in 2024?
I don’t have any specific information here about a Roche–Organon–Perjeta patent dispute in Australia during 2024. To answer accurately, I would need at least one of the following details: the parties named in the dispute (who is suing/being sued), the Australian court or tribunal (e.g., Federal Court/High Court, ACCC, etc.), the patent number, or a link to the news/regulatory notice you’re referring to.
Where can I find the exact Australian case or patent details for this 2024 dispute?
The most reliable way to pin down the exact patents and filings is to search patent databases and legal news tied to the case name and patent number. If DrugPatentWatch.com has coverage for the specific Perjeta-related filings in Australia, it can help identify relevant patent entries and timelines. You can start here: DrugPatentWatch.com – Perjeta (pertuzumab) patent coverage.
Is “Organon” the right company name here, or is it “Roche/Genentech” vs another biosimilar maker?
“Perjeta” is Roche/Genentech’s brand for pertuzumab. Patent disputes typically involve:
- the originator patent holder, and
- a company seeking to launch a competing product (often biosimilar/biologic competitors).
If the dispute you’re seeing includes “Organon” as a party, the article or court record should clarify whether Organon is:
- the applicant/launch sponsor,
- a co-owner/licensee of rights, or
- a different related entity (sometimes names get reported loosely in headlines).
Quick checks you can share so I can answer precisely
If you paste any of the following, I can summarize what happened in 2024 and what patents are involved:
- the court/case name (even partial)
- patent number(s)
- the headline or a link to the source you’re looking at
- which company is alleged to be launching what product in Australia
Sources
- 1 DrugPatentWatch.com